Literature DB >> 2285629

Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol.

T R Pedersen1, M Kantor.   

Abstract

Treatment with nisoldipine (2 x 10 mg tablets once daily) and nifedipine (2 x 10 mg capsules three times daily) in patients with severe, but stable effort angina pretreated with atenolol (100 mg once daily in 19 patients and 50 mg once daily in one patient) were compared for their effects on bicycle exercise tolerance and their adverse effects in a randomized 2 x 4 week, double-blind, double-dummy crossover study. All patients had multivessel disease, 16 patients had occlusion of at least one vessel, and eight patients had a history of myocardial infarction. Two patients left the study during the initial nisoldipine period, one because of aggravation of the angina and the other because of suspected allergic reaction. Addition of nifedipine to atenolol treatment significantly improved the variables measured for severity of angina, such as time of exercise until 1 mm and 2 mm ST-segment depression, total exercise time and total workload. In contrast, no such improvement was noted after the addition of nisoldipine to atenolol. However, nisoldipine resulted in a significant prolongation of the time to the initiation of chest discomfort, the maximum heart rate, and the double product. In atenolol-treated patients with severe effort angina pectoris, nifedipine 20 mg tid improved exercise capacity, while nisoldipine 20 mg once daily did not have a similar effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285629     DOI: 10.1007/bf01857753

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  7 in total

1.  A dose-ranging, placebo-controlled, double-blind trial of nisoldipine in effort angina: duration and extent of antianginal effects.

Authors:  J Lam; B R Chaitman; P Crean; R Blum; D D Waters
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

2.  Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist.

Authors:  D C Warltier; C M Meils; G J Gross; H L Brooks
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

3.  Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).

Authors:  S Kazda; B Garthoff; H Meyer; K Schlossmann; K Stoepel; R Towart; W Vater; E Wehinger
Journal:  Arzneimittelforschung       Date:  1980

4.  Hemodynamic effects of the new vasodilator drug Bay k 5552 in man.

Authors:  A Vogt; K L Neuhaus; H Kreuzer
Journal:  Arzneimittelforschung       Date:  1980

5.  Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade.

Authors:  D C Warltier; M G Zyvoloski; G J Gross; H L Brooks
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

6.  [Anti-angina effectiveness of the calcium antagonist nifedipine in relation to coronary involvement].

Authors:  W Schulz; S Jost; M Kaltenbach; G Kober
Journal:  Z Kardiol       Date:  1983-11

7.  Effect of nisoldipine upon the general and coronary hemodynamics of the anesthetized dog.

Authors:  G M Maxwell; S Crompton; V Rencis
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

  7 in total
  2 in total

Review 1.  Calcium channel antagonists. Part V: Second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

Review 2.  North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. North of England Stable Angina Guideline Development Group.

Authors: 
Journal:  BMJ       Date:  1996-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.